133 related articles for article (PubMed ID: 10649524)
1. Mesothelial hyperplasia with reactive atypia: diagnostic pitfalls and role of immunohistochemical studies-a case report.
Lee A; Baloch ZW; Yu G; Gupta PK
Diagn Cytopathol; 2000 Feb; 22(2):113-6. PubMed ID: 10649524
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
3. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
6. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
8. Utility of HBME-1 immunostaining in serous effusions.
Ascoli V; Carnovale-Scalzo C; Taccogna S; Nardi F
Cytopathology; 1997 Oct; 8(5):328-35. PubMed ID: 9313985
[TBL] [Abstract][Full Text] [Related]
9. [Recurrent pericarditis related to primary pericardial malignant mesothelioma].
Smets P; Guettrot-Imbert G; Hermet M; Delevaux I; Kemeny JL; Aumaître O; André M
Rev Med Interne; 2013 Sep; 34(9):573-6. PubMed ID: 23773902
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical differentiation of reactive from malignant mesothelium as a diagnostic aid in canine pericardial disease.
Milne E; Martinez Pereira Y; Muir C; Scase T; Shaw DJ; McGregor G; Oldroyd L; Scurrell E; Martin M; Devine C; Hodgkiss-Geere H
J Small Anim Pract; 2018 May; 59(5):261-271. PubMed ID: 29607509
[TBL] [Abstract][Full Text] [Related]
12. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
13. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
14. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
Henderson DW; Shilkin KB; Whitaker D
Am J Clin Pathol; 1998 Sep; 110(3):397-404. PubMed ID: 9728617
[TBL] [Abstract][Full Text] [Related]
15. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
16. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies.
Ghosh AK; Gatter KC; Dunnill MS; Mason DY
J Clin Pathol; 1987 Jan; 40(1):19-25. PubMed ID: 2434531
[TBL] [Abstract][Full Text] [Related]
17. Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology.
Patil B; Shivkumar V; Gangane N
Indian J Pathol Microbiol; 2018; 61(1):90-93. PubMed ID: 29567891
[TBL] [Abstract][Full Text] [Related]
18. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
19. Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology.
Malle D; Valeri RM; Photiou C; Kaplanis K; Andreadis C; Tsavdaridis D; Destouni C
Acta Cytol; 2005; 49(1):11-6. PubMed ID: 15717748
[TBL] [Abstract][Full Text] [Related]
20. Embolized mesothelial cells within mediastinal lymph nodes of three dogs with idiopathic haemorrhagic pericardial effusion.
Peters M; Tenhündfeld J; Stephan I; Hewicker-Trautwein M
J Comp Pathol; 2003; 128(2-3):107-12. PubMed ID: 12634086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
